Results 201 to 210 of about 2,143 (224)

The therapeutic potential of nicotine and nicotinic agonists for weight control

Expert Opinion on Investigational Drugs, 1999
Transdermal nicotine patches have been successfully introduced as a safe and powerful aid to smoking cessation; this has contributed to the rising interest in additional therapeutic applications for nicotine and synthetic nicotinic agonists. Nicotine and nicotinic agonists may have a therapeutic potential for a variety of disorders, including Alzheimer'
openaire   +3 more sources

Epibatidine, a novel nicotinic receptor agonist [PDF]

, 1994
It is speculated that nicotine receptor ligands might be of therapeutic benefit for the treatment of obesity, anxiety, and memory loss. With the exception of nicotine, few selective high-affinity agents exist. (-)Epibatidine (1), isolated from Ecuadoran frogs, shows structural resemblence to (-)nicotine (2). Molecular modeling studies reveal that the N
T. McHugh, Marietta Piattoni-Kaplan, W. Glassco, Anthony W. Bannon, James P. Sullivan, D. M. Wypij, Michael W. Decker, Richard A. Glennon, J. McKay, Malgorzata Dukat, Stephen P. Arneric, Diana L. Donnelly-Roberts, May El, Billy R. Martin, T. Y. Shen, R. H. Loring, Murali Gopalakrishnan, K. R. Creasy, David J. Anderson, M. I. Damaj, X. Zhang, John A. Rosecrans, D. Dumas   +22 more
openaire   +1 more source

Decamethonium is a partial agonist at the nicotinic acetylcholine receptor

Synapse, 1993
AbstractThe efficacy of decamethonium as an agonist at the nicotinic acetylcholine receptor has never been determined. Here, we demonstrate how patch clamp recording during rapid perfusion of agonists to outside‐out patches from BC3H‐1 cells can be used to provide an unambiguous estimate of the efficacy of decamethonium.
James P. Dilger, Yi Liu
openaire   +2 more sources

Nicotine effects on the activity of mice exposed prenatally to the nicotinic agonist anatoxin-a

Neurotoxicology and Teratology, 2005
Anatoxin-a is a nicotinic agonist produced by several genera of cyanobacteria, and has caused numerous deaths of wildlife, livestock and domestic animals world-wide. Several studies in the literature have shown that exposure of mice and rats to nicotine early in development alters its effects when the rodents are subsequently challenged with nicotine ...
Neil Chernoff, Jackie D. Farmer, Robert C. MacPhail, K.A. Jarema   +3 more
openaire   +3 more sources

Epibatidine, a potent analgetic and nicotinic agonist.

Molecular Pharmacology, 1994
Synthetic (+)- and (-)-epibatidine (an alkaloid originally characterized from frog skin) have potent analgetic activity in mice, using the hot-plate assay. The natural (+)-enantiomer, with an ED50 of about 1.5 micrograms/kg upon intraperitoneal injection, is about 2-fold more potent than the (-)-enantiomer.
B, Badio, J W, Daly
openaire   +2 more sources

Discriminative stimulus properties of the nicotinic agonist cytisine

Psychopharmacology, 1997
Cytisine binds with high affinity and specificity to neuronal nicotinic receptors but its physiological and behavioural effects are complex and differ from those of nicotine. The present study explores the behavioural aspects further by comparing the discriminative stimulus effects of cystisine with those of nicotine. Two groups of rats were trained to
Chris Chandler, I.P. Stolerman
openaire   +3 more sources

Neuronal nicotinic acetylcholine receptor agonists

Expert Opinion on Therapeutic Patents, 2004
Nicotinic acetylcholine receptors (nAChRs) consist of five protein subunits surrounding a central ion channel.
TOMA, LUCIO, BARLOCCO Daniela, GELAIN Arianna   +2 more
openaire   +3 more sources

ABT — 418, a Novel Nicotinic Agonist

1994
With the plethora of receptor targets evolving as the result of nicotinic acetylcholine receptor (nAChR) cloning it is possible that new molecular entities selective for subtypes of nAChRs can be developed which are potentially free of the side effect liabilities associated with (-)-nicotine.
Jorge D. Brioni, M. W. Decke, Yvonne C. Martin, S. P. Amend, David J. Anderson, James R. Pauly, M. J. Buckley, J. T. Wasicak, A. D. Rodrigues, James R. Pauly, P. A. Pavlik, Michael W. Decker, David S. Garvey, M. Majchrzak, Diana L. Donnelly-Roberts, Stephen P. Arneric, Alyssa B. O'Neill, Mark W. Holladay, Richard J. Radek, Jerry J. Buccafusco, Alvin V. Terry, Scott F. Robinson, D. J. B. Kim, Peter Curzon, James P. Sullivan, K. C. Marsh, Susan Wonnacott, William J. Jackson, G. Wilkie, S C Quigley, Kennan C. Marsh, Michael Williams   +31 more
openaire   +2 more sources

NICOTINIC AGONIST MODULATION OF FELINE BRONCHOMOTOR TONE

Clinical and Experimental Pharmacology and Physiology, 1990
SUMMARY1. The bronchomotor actions of three nicotinic cholinoceptor agonists were investigated in anaesthetized, mechanically ventilated cats. The agonists were administered intravenously after increasing baseline airways smooth muscle tone with an infusion of 5‐hydroxytryptamine.2.
Louis Diamond, Ralph J. Altiere, David C. Thompson   +2 more
openaire   +3 more sources

Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists.

Ciba Foundation symposium, 1990
Although numerous studies have demonstrated that chronic nicotine treatment often results in tolerance to this drug, the mechanisms that underlie this tolerance are not well defined. Recent evidence suggests that chronic nicotine treatment results in an up-regulation of brain nicotinic receptors, but the majority of these receptors may be desensitized ...
James R. Pauly, Michael J. Marks, Ratan V. Bhat, Allan C. Collins   +3 more
openaire   +3 more sources